Don't let it happen to you again.
Anybody who understands the science knows just how valuable this company is.
Take that blogger Dirk H. who this time last year posted one after another putting down ARWR while boosting TKMR.
All because ARWR was getting away from him after he booked profit to roll it into the TKMR laggard.
At the earliest opportunity Dirk H. dumped TKMR and put more than half his portfolio into ARWR.
This is the man responsible for the fixation on single dose KD the shorts used to decimate this stock.
Dirk H. is the poster boy for the kind of greed we have to deal with when the stake is so high.
This is not just another bio, with shorts to the tune of one quarter of the shares being traded.
ARWR is that important and that valuable that people will sell their soul in their ulterior motive.
"As I have revealed, I had once held 40,000 shares of AAPL that I bought in around 1997 for $1 but I sold them long before they became worth $300 M today." - end2war (May 1, 2015)
Let that be the object lesson to you all.
The old man passed up on $300 million because after taking up that incredible position he spent his time on AAPL messageboard whining and doubting and selling his position down to 0.
Don't let this happen to you.
AAPL is a $740 billion company today while GILD is $160 billion.
ARWR can be bigger than GILD.
We're preparing for a lift-off.
Passengers, please proceed to gate no. 7 immediately.
The rocket is filled to overflowing with short fuel.
Countdown has started.
I'm not sure it'll take a year.
This company is very valuable.
Just as valuable as ALNY if not soon to be much more.
You can not know what is going on in the background.
But would it really surprise anyone if there is suddenly news?
in this stock.
You have to admire their manly qualities next to the whimpering longs wallowing in doubts.
Look what bold risks they actively take and monitor the stock when all the longs have to do is buy and hold.
Imagine if you go into a coma today to wake up at some future date.
over the size of their peters.
Every day is a what-if day.
They have no confidence in what they hold in their hand.
Even as they flog it to death day in day out.
Men of experience try to tell the "little" boys what's important.
But they would have none of it, the little minds are quite fixated.
less than $400 million market cap.
You know what to do.
And if you don't, it's time to go end the war elsewhere.
For here the battle rages and the war is just getting started.
A for Atomic ARWR will end this war and reign supreme for the coming decades.
would have you believe that ARWR is a one-trick pony.
Nothing could be further from the truth.
ARC-AAT with outstanding preclinical has entered phase 1 testing.
And it's done in less than two years!!!
Two more targets are in preclinical.
One is entering preIND, the other is an extrahepatic target!
Novartis after vetting chose ARWR to deliver their three targets in preclinical.
And in the process becoming the second largest share holder.
Needless to say, they had been shown DPC now going subQ.
The thesis of the DPC railroad fast-tracking drug development is playing out right in front of your eyes.
In this field there is ALNY prodding along and there is ARWR leapfrogging.
At this moment ALNY is $105 with $10 billion market cap, ARWR is $7 with
Sentiment: Strong Buy
Seriously, all you have to do is look at the price.
If ALNY is triple-digit, there is simply no way ARWR would be single-digit.
People somehow have been brainwashed into ignoring the FACT that ARWR is as big a player as ALNY.
Single digit for ARWR at this point in time is utter insanity.
And the parade of longs who come on the board posting justifying it testify to their mental condition.
They have been held captive for so long they would believe anything their captors tell them.
Say hi and immediately they drop their pants and bend over grabbing their ankles saying thank you, sir.
The best part of the development is the following:
According to Street Insider, "Novartis has been working in the RNAi field for over a decade and their developments in proprietary oligonucleotide formatting and modifications are some of the best we've seen. We anticipate this acquisition will provide us with substantially expanded freedom to operate, proprietary technology that appears to enhance the activity of RNAi triggers, access to non-delivery Alnylam RNAi IP for 30 targets, and three programs that went through the rigorous Novartis vetting process," said Christopher Anzalone, Ph.D., President and Chief Executive Officer of Arrowhead Research.
Arrowhead was particularly interested in Novartis's pipeline of three candidates that have developed pre-clinical data.
Three drug candidates with promising preclinical data.
Roche is handing them over to ARWR to deliver the drugs via DPC and becoming the second largest shareholder.
This is the testament from big drug you were looking for but too dumb to remember a month later.
I said it many times before and here are the pieces that are falling in place right before your very eyes.
ARWR is as big a player as ALNY and soon to be bigger.
How's that for statements made at least a year in advance.
And nothing but nothing is detracting from that projection.
Bust the shorts, which we will soon, not if, and off to the races we go!
"The deal gives Arrowhead the freedom to operate in any target for any indication, strengthening the belief that RNAi therapeutics is a bilateral field - there's Alnylam and there's Arrowhead, Chief Executive Christopher Anzalone told Reuters."
In this bilateral field, ALNY is triple-digit, ARWR is single-digit with 1 out of 4 shares trading short.
Needless to say there is something seriously out of whack here.
Without the HUGE short shares this thing would be double-digit at least and on the way to triple-digit.
I invite any and all to point out the shortcomings of ARWR science where we are competing.
There seems to be a number of posters who claim to be long and post day in and day out justifying ARWR trading in the single digit.
Beware of their ulterior motives if not gullibility.
Nothing could be further from the truth.
March 5 (Reuters) - Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins.
The deal gives Arrowhead the freedom to operate in any target for any indication, strengthening the belief that RNAi therapeutics is a bilateral field - there's Alnylam and there's Arrowhead, Chief Executive Christopher Anzalone told Reuters.
Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.
French drugmaker Sanofi SA bought a 12 percent stake in Alnylam Pharmaceuticals Inc for $700 million last year.
Ribonucleic acid interference (RNAi) therapy has stirred the interest of drugmakers as it aims to silence certain genes to inhibit the production of disease-causing proteins.
Available therapies, including monoclonal antibodies, try to inactivate these proteins by binding to them.
The deal announced on Thursday gives Arrowhead access to Novartis' RNAi portfolio and associated assets, including various patents and three drugs in the preclinical stage.
It also includes a component that could enhance the efficiency of Arrowhead's RNAi triggers, and provides access to some Alnylam intellectual property on 30 gene-targets hand-picked by Novartis.
"It's a complicated and unsettled IP landscape and we have just increased our freedom here," Anzalone said.
Alnylam and another major competitor, Isis Pharmaceuticals Inc, extended their partnership earlier this year to cross-license IP on four disease-targets.
Thursday's transaction, which also includes a $10 million cash component, is reminiscent of a 2011 deal between Arrowhead and Roche Holding AG, where Roche transferred its RNA assets in exchange for a stake.
end2war: You are increasingly playing dumb games and your comments have turned to insults, which is never productive of discussion.
Are you talking about yourself? Look back on the thread to see who started the insult: dreamer, day trader, etc.
end2war: What science? That is what they are discovering in the trials.
Lame. The science is the backbone. What they are discovering in the trials are data points. Heretofore all data points conform to the science backbone.
end2war: You make a lot of one liner claims. I But, you have not contributed one single iota of substance to support your position that ARWR is a 99% sure bet. That is because you have no real expertise, and like to just make argumentative claims.
You exhibit zero ability for logical argument.
This thread starts with my proposing that ARWR's science is 99% believable. That is to say that it is believable but allowing for the reality that nothing is 100%.
You come on a high horse saying that it's not.
I invite you to point out where any of the scientific results so far are inconsistent and may lead to doubting the veracity and viability of DPC.
Au contraire, "YOU have not contributed a single iota of" scientific evidence to detract from my statement on the believability of the science.
In stead you cite the shorts' action all the way to ARWR's Safe Harbor caveat. none of it addresses the science directly.
It's really time to put up or shut up. You clearly have too much time or your hand and engage in this and that thread all day and ad nauseam, regurgitating the same thing over and over that you are long but without a clue.
$10 billion is just one drug.
DPC is about pumping out drugs you don't even know yet.
I'm getting tired of saying that the future of this company is wide open.
By wide open I mean wide open as in W-I-D-E OPEN, somebody please get it already.
DPC is just getting started.
That Dirk H. trained all the Pavlov dogs to jump off the cliff with 1-2 mg/kg DPC first gen results.
See who bought ARWR heavily after getting it to sell off before and after October 8th.
Of course, after, the shepherd boy screamed himself hoarse that it didn't matter but none of the village idiots would listen anymore.
You need a refresher course in logic.
Or perhaps you weren't clear that by contrary evidence I meant, "to the science," which should otherwise be clear to a reader of average reading comprehension.
For example, 1-2, What "shorts, analysts, dogs and crooks" do are not contrary evidence to the science. When I say the sky is blue because I measure the reflected light from the sky and find the predominant spectra to fall in the blue region, you quoting some other people saying that the sky is red in itself does not present an evidence contrary to my finding.
By the same token, 4-7, equally nonscientific and quite contrived.
That leaves 3 with simply negative twists on the 1 and 2 mg/kg single doses data.
Examination only reveals poor logical reasoning. For example, "just 12 patients," - your logic instructor will educate you that this would not in itself be a contrary evidence. And "they were in China!" smacks of some kind of racism or provincialism. You ought to know that the very computer you are using to denigrate foreigners is likely made by them and probably just about everything else making your life comfortable. If the US is shut off from the world this country would simply implode.
The results at 1-2 mg/kg stand along the long line of previous preclinical data and conform well. With the exception of persistence which was much better than expected.
You and many socalled longs here have been fed so much Kool-Aid by the shorts and regurgitating Stockholm syndrome out of your ears.
I find it comical the amateur scientists' daily dissection and prediction of 1-2-3-4 mg/kg single dose results. Be the last person after that Dirk H. long got it and reporting from the people actually working on the problem that it's really academic. Of course, ARWR tried to tell you all whose ears were stuffed with Kool-Aid and drowned by the din of "shorts, analysts, dogs and crooks" barking.
And it looks to be everything we've anticipated, and more.
Look at that persistence of effect.
You can not put a price on this company.
Move over ALNY, this here ARWR is THE real triple-digit stock.
And dare I say, quadruple-digit stock when all cylinders start cranking out the drugs.
This company could define biotech for the coming decades.
Sentiment: Strong Buy
Never mind the naysayers.
Buy this stock, whatever you can afford.
Forget about the house, later on you can buy a mansion, or several.
Pass on that shiny hunk of metal that will soon turn to rust and put your money in something that will turn to gold.
Is there such a thing as a sure thing?
It depends on how much you believe in science.
Probabilities are never 100% or 0%.
But at some point you gotta to believe in something.
It helps if the probability calculates out to 99%.
I have yet to see any evidence contrary to my belief.
Sentiment: Strong Buy